M. Kozloff

455 total citations
29 papers, 352 citations indexed

About

M. Kozloff is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, M. Kozloff has authored 29 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 3 papers in Genetics. Recurrent topics in M. Kozloff's work include Colorectal Cancer Treatments and Studies (17 papers), Cancer Treatment and Pharmacology (16 papers) and Gastric Cancer Management and Outcomes (7 papers). M. Kozloff is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Cancer Treatment and Pharmacology (16 papers) and Gastric Cancer Management and Outcomes (7 papers). M. Kozloff collaborates with scholars based in United States, France and Greece. M. Kozloff's co-authors include Axel Grothey, Allen Lee Cohn, Herbert I. Hurwitz, Tanios Bekaii‐Saab, Johanna C. Bendell, E. Dawn Flick, Nancy Roach, Darshan Dalal, Mary M. Sugrue and Susan Fish and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

M. Kozloff

29 papers receiving 346 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Kozloff United States 12 273 138 64 54 54 29 352
Nicolas Sommer United States 11 260 1.0× 107 0.8× 74 1.2× 36 0.7× 107 2.0× 27 356
Olivia Wilkins United States 5 309 1.1× 183 1.3× 26 0.4× 37 0.7× 28 0.5× 5 360
Axel Florschütz Germany 8 195 0.7× 70 0.5× 68 1.1× 28 0.5× 108 2.0× 16 254
Filomena Del Gaizo Italy 10 188 0.7× 150 1.1× 20 0.3× 95 1.8× 37 0.7× 20 423
Sabine Berendse United Kingdom 8 184 0.7× 71 0.5× 21 0.3× 29 0.5× 31 0.6× 10 292
Jacopo Giuliani Italy 12 206 0.8× 194 1.4× 19 0.3× 39 0.7× 34 0.6× 76 391
J McKendrick Australia 9 338 1.2× 180 1.3× 38 0.6× 121 2.2× 96 1.8× 24 525
Swee‐Peng Yap Singapore 7 287 1.1× 255 1.8× 45 0.7× 100 1.9× 98 1.8× 9 532
M. Neubauer United States 10 196 0.7× 182 1.3× 15 0.2× 18 0.3× 47 0.9× 20 304
Katia Dotti Italy 12 364 1.3× 149 1.1× 58 0.9× 91 1.7× 114 2.1× 28 514

Countries citing papers authored by M. Kozloff

Since Specialization
Citations

This map shows the geographic impact of M. Kozloff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Kozloff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Kozloff more than expected).

Fields of papers citing papers by M. Kozloff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Kozloff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Kozloff. The network helps show where M. Kozloff may publish in the future.

Co-authorship network of co-authors of M. Kozloff

This figure shows the co-authorship network connecting the top 25 collaborators of M. Kozloff. A scholar is included among the top collaborators of M. Kozloff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Kozloff. M. Kozloff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luke, Jason J., Steven J. Chmura, Jacob B. Allred, et al.. (2018). A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605).. Journal of Clinical Oncology. 36(15_suppl). TPS9599–TPS9599. 4 indexed citations
2.
Marsh, Robert, Marshall S. Baker, Daniel V.T. Catenacci, et al.. (2016). Peri-operative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PDAC): A pilot study.. Journal of Clinical Oncology. 34(4_suppl). 312–312. 3 indexed citations
3.
4.
Vos, Sven de, Christopher R. Flowers, Ding Wang, et al.. (2014). The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma. Blood. 124(21). 1722–1722. 12 indexed citations
5.
Pashos, Chris L., Christopher R. Flowers, Neil E. Kay, et al.. (2013). Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Supportive Care in Cancer. 21(10). 2853–2860. 29 indexed citations
6.
Lin, Nancy U., Lee S. Schwartzberg, Santosh Kesari, et al.. (2013). Abstract B76: A phase II study of ANG1005, a novel, brain-penetrant taxane derivative, in breast cancer patients with brain metastases.. Molecular Cancer Therapeutics. 12(11_Supplement). B76–B76. 1 indexed citations
7.
8.
9.
Kozloff, M., Tanios Bekaii‐Saab, Johanna C. Bendell, et al.. (2011). Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS).. Journal of Clinical Oncology. 29(15_suppl). 3625–3625. 15 indexed citations
10.
Blay, Jean‐Yves, Aňa Lluch, Miguel Martín, et al.. (2009). Sunitinib (SU) in Combination with Trastuzumab (T) for the Treatment of Advanced Breast Cancer (ABC): Activity and Safety Results from a Phase II Study.. Cancer Research. 69(24_Supplement). 201–201. 3 indexed citations
11.
Sugrue, Mary M., M. Kozloff, John D. Hainsworth, et al.. (2007). 3048 POSTER Safety and effectiveness of bevacizumab (BV) plus chemotherapy (CT) in elderly patients with mCRC: results from the BRiTE registry. European Journal of Cancer Supplements. 5(4). 250–250. 7 indexed citations
12.
Kozloff, M., John D. Hainsworth, Suprith Badarinath, et al.. (2007). 3049 POSTER Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT). European Journal of Cancer Supplements. 5(4). 250–251. 12 indexed citations
13.
14.
Sugrue, Mary M., Yi Jiang, D. Purdie, et al.. (2007). 3045 POSTER Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): results from the BRiTE registry. European Journal of Cancer Supplements. 5(4). 249–249. 2 indexed citations
15.
16.
Kindler, Hedy L., Kathryn Bylow, H. S. Hochster, et al.. (2006). A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis. Journal of Clinical Oncology. 24(18_suppl). 4040–4040. 15 indexed citations
17.
Kozloff, M., Allen Lee Cohn, Patrick J. Flynn, et al.. (2005). Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S. Journal of Clinical Oncology. 23(16_suppl). 3566–3566. 17 indexed citations
18.
Calhoun, Elizabeth A., Sheila O. Brown, M. Kozloff, & Charles L. Bennett. (2005). Uncompensated costs associated with the outpatient management of cancer chemotherapy-associated febrile neutropenia. Community Oncology. 2(4). 293–296. 2 indexed citations
19.
Boccia, Ralph V., Pramila R. Anné, Jean Bourhis, et al.. (2004). Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). International Journal of Radiation Oncology*Biology*Physics. 60(1). 302–309. 24 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolas Sommer Breakdown of academic impact, for papers by Olivia Wilkins Breakdown of academic impact, for papers by Axel Florschütz Breakdown of academic impact, for papers by Filomena Del Gaizo Breakdown of academic impact, for papers by Sabine Berendse Breakdown of academic impact, for papers by Jacopo Giuliani Breakdown of academic impact, for papers by J McKendrick Breakdown of academic impact, for papers by Swee‐Peng Yap Breakdown of academic impact, for papers by M. Neubauer Breakdown of academic impact, for papers by Katia Dotti
Rankless by CCL
2026